What is the difference between ARA-290 and Cerluten?

ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing Cerluten: CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Cerluten administered in research settings?

In research settings, Cerluten is typically administered via the oral or subcutaneous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ARA-290 vs Cerluten

Peptide Comparison

ARA-290 vs Cerluten

Name: ARA-290 vs Cerluten — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

16 providers listed

Full ARA-290 profile →

Cerluten

brain peptide bioregulator

LongevityResearch Only

1 providers listed

Full Cerluten profile →

Bottom line

ARA-290 carries stronger published evidence (RCT, 3 key studies) than Cerluten (Review, 2); both are research compounds.

Quick Verdict

ARA-290

Evidence

Clinical

Half-life

~2 min (IV); ~10–20 min (SC)

Cerluten

Evidence

Review-level

Half-life

—

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	ARA-290
Further along in FDA review	ARA-290
Oral administration option	Cerluten
More provider options (16 vs 1)	ARA-290

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ARA-290

Cerluten

Mechanism Family

Longevity & Cellular

Half-life

~2 min (IV); ~10–20 min (SC)

—

FDA Status

investigational

unknown

Admin Routes

subcutaneous, intravenous

oral, subcutaneous

Availability

Research Only

Providers

16 listed

1 listed

Avail. Notes

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

—

Research Evidence

ARA-290

ClinicalRCT · 3 key studies · most recent 2026

Cerluten

Review-levelReview · 2 key studies · most recent 2022

Research Citations

ARA-290

Cohort2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

RCT2015 · Molecular Medicine

ARA 290, a non-hematopoietic erythropoietin analogue, improves metabolic control and neuropathic symptoms in…

Cerluten

Review2022 · International Journal of Molecular Sciences

Peptide Regulation of Gene Expression and Protein Synthesis in Bronchial Epithelium

Review2021 · Molecules

Peptide Regulation of Gene Expression: A Systematic Review

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About Cerluten

CNS-targeted peptide complex that modulates neuronal gene expression. Shown in Russian clinical studies to improve memory consolidation, attention, and protect against neurodegeneration.

Research Areas

neuroprotectioncognitive supportmemoryanti-aginglongevity

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

Cerluten

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

ARA-290

$5.00/mg

$4.00 – $5.42 range

17 vendors

View price index →Find providers →

Cerluten

Not enough vendor pricing yet.

Find Providers

Where to source these peptides

Providers offering

ARA-290

16 listed

Browse directory →

Providers offering

Cerluten

1 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 27, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs Cerluten — Per-mg Price Comparison. Retrieved July 29, 2026, from https://peptidebase.io/peptides/compare/ara-290/cerluten

https://peptidebase.io/peptides/compare/ara-290/cerluten Methodology License Download JSON Download CSV